Dr. Alain Vertès is Managing Director at NxR Biotechnologies, a boutique global consulting firm based in Basel, Switzerland, where he advises clients on strategy, business development, in/out-licensing, entrepreneurship and investment. He brings to this role extensive experience in the pharmaceutical and industrial biotechnology sectors, in Europe, North America and Asia and in different functions including research, manufacturing, contract research, and strategic alliances. NxR's track record comprises projects with big pharmas, biotechs, generics companies, financial investors, CROs, academia, and start-ups. Active VP of Alliance Management at Mesoblast, prior to NxR Biotechnologies, Dr. Vertès held positions of increasing responsibility in pharmaceuticals at Lilly and Pfizer, and led the global cell therapeutics strategy and implementation team from 2007-2010 at Roche. In addition, he has worked in petrochemicals at Mitsubishi Chemical Corporation, public research at the Institut Pasteur and RITE/Kyoto, contract research at Battelle Memorial Institute and PPD|BioDuro, and has done consulting for the Australian Strategic Policy Institute. With a focus on innovation commercialization, he has been a key player in the evaluation, selection, deal making, implementation and alliance management of numerous novel products and emerging technologies.
Dr. Vertès received his M.Sc. degree from the University of Illinois at Urbana-Champaign, his Ph.D. from the University of Lille Flandres Artois, and is a Sloan Fellow from London Business School (MBA/M.Sc.). Dr Vertès is a lead editor of several science and strategy books in the fields of regenerative medicine and sustainable chemistry.